Leo Cancer Care’s Marie® Solution Enables World’s First Clinical Upright Proton Therapy Treatment at Stanford Medicine

New milestone demonstrates how upright radiotherapy can expand access to proton therapy while transforming the treatment experience.

Leo Cancer Care today announced that its Marie® upright patient positioning and imaging platform has enabled the introduction of upright proton therapy delivery at the Stanford Medicine Cancer Center, delivered by the Mevion S250-FIT™ Proton Therapy System, powered by RayStation from RaySearch Laboratories. The milestone represents the first patient treatment using the combined Mevion and Leo Cancer Care upright proton therapy configuration.

A Treatment That Has Long Been Out of Reach

Developed through partnership between Leo Cancer Care and Mevion Medical Systems, the integrated solution combines compact proton therapy with upright patient positioning and imaging – creating a new model for proton therapy delivery designed to reduce infrastructure barriers, improve patient experience, and support broader global access to advanced radiotherapy.

The treatment represents a major step forward in the evolution of upright radiotherapy and validates a fundamentally different approach to proton therapy system design. Rather than rotating a large proton gantry around the patient, the Marie® platform rotates the patient in relation to a fixed proton beam. This removes the need for large rotating gantries and can enable proton therapy systems to be installed within existing LINAC vaults rather than requiring purpose-built proton facilities.

“This milestone represents an important moment not only for Leo Cancer Care, but for the future direction of radiation oncology. For decades, proton therapy has delivered remarkable clinical benefits but has remained limited by the scale, complexity, and infrastructure demands of traditional systems. By enabling treatment in an upright position using a fixed-beam approach, we are helping redefine how proton therapy can be delivered- making it more compact, more flexible, patient-centered, and potentially accessible to far more patients around the world.”

Stephen Towe, CEO and Co-founder of Leo Cancer Care

Read the news from Stanford Medicine Cancer Center

*Photo credit: Steve Fisch/Stanford Medicine.